Voyager Therapeutics, Inc.
VYGR
$3.77
-$0.18-4.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 157.02% | -19.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 157.02% | -19.67% | |||
| Cost of Revenue | 14.48% | -0.62% | |||
| Gross Profit | 13.89% | -4.30% | |||
| SG&A Expenses | -22.89% | 8.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.10% | 1.60% | |||
| Operating Income | 16.47% | -5.57% | |||
| Income Before Tax | 16.66% | -7.69% | |||
| Income Tax Expenses | 453.33% | -59.46% | |||
| Earnings from Continuing Operations | 16.45% | -7.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.45% | -7.61% | |||
| EBIT | 16.47% | -5.57% | |||
| EBITDA | 16.59% | -5.59% | |||
| EPS Basic | 16.64% | -7.04% | |||
| Normalized Basic EPS | 16.85% | -7.11% | |||
| EPS Diluted | 16.79% | -7.22% | |||
| Normalized Diluted EPS | 16.85% | -7.11% | |||
| Average Basic Shares Outstanding | 0.23% | 0.54% | |||
| Average Diluted Shares Outstanding | 0.23% | 0.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||